Skip to main content
Premium Trial:

Request an Annual Quote

Michael Olex, Mark Philip

RainDance Technologies this week announced the appointment of Michael Olex as vice president of system development, effective immediately.
Olex joins RainDance from BioTrove, where he was vice president of manufacturing, and established the company's OpenArray consumable and instrumentation manufacturing departments. He also served as senior vice president at US Genomics; president of International Light; director of business projects at Applied Biosystems; and vice president of manufacturing at PerSeptive Biosystems

Mark Philip has been appointed the new president and chief executive officer of Znomics, the company announced this week. He succeeds Richard Sessions, Znomics co-founder and interim CEO, who will remain as a consultant to the company and as an active member of Znomics' board of directors.
Philip was most recently president of Stryker Biotech. Prior to Stryker Biotech, he was president and chief executive officer of Zycos. Philip previously served as president and chief executive officer of Immuno-US. Prior to Immuno-US, he held a number of international executive management positions at Baxter International in Europe, the US, and Japan, before which he was employed by Schering-Plough Pharmaceuticals.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.